SEGMENT REPORTING

We are currently developing therapies for the treatment of hematologic malignancies. To date, our only

source of product revenue has been from U.S. sales of RYTELO, which began shipping to customers in June 2024.

Additionally, we have generated insignificant royalty and license fee revenue under agreements that out-license technology

to various companies.

For the year ended December 31, 2025, we have identified one operating and reportable segment. We

define our operating segments based on internally reported financial information that is regularly reviewed by the Chief

Operating Decision Maker or CODM to analyze financial performance, make decisions, and allocate resources. Our Chief

Executive Officer is the CODM.

The CODM reviews the segment's profit or loss based on net (loss) income reported on the consolidated

statement of operations and comprehensive (loss) income and considers forecast-to-actuals variances on a quarterly basis

for expenses that are deemed significant. Further, the CODM reviews the segment's assets based on total assets reported on

the consolidated balance sheet. All long-lived assets are held in the U.S. Further, the CODM reviews the segment's assets

based on total assets reported on the consolidated balance sheet. All long-lived assets are held in the United States.

Our CODM views specific categories within research and development expenses and selling, general and

administrative expenses as significant given the correlation between cash burn and profitability. The following table

reconciles reported revenues to net (loss) income under the significant expense principle for the year ended December 31,

2025 and 2024:


	Year Ended December 31,
(in millions)	2025	2024
Revenues:
Product revenue, net	183.6	76.5
Royalties	0.3	0.5
Total revenues	$183.9	$77.0
Operating expenses:
Cost of goods sold	4.7	1.3
Research and development
Research and clinical expenses	54.2	67.9
Chemistry, manufacturing, and control expenses	9.8	26.2
Restructuring charges	8.6	—
Selling, general and administrative
Commercial expenses	78.6	72.0
Restructuring charges	8.4	—
Other segment expenses*	88.2	83.3
Total operating expenses	$252.5	$250.7
Loss from operations	(68.6)	(173.7)
Total interest and other income (expense)	(14.9)	(0.9)
Net loss	$(83.5)	$(174.6)

*Other segment expenses includes stock-based compensation expense and other general and administrative expenses

largely resulting from personnel costs for individuals in administrative functions and legal and professional fees.

Accordingly, the Company consists of a single operating and reportable segment and the consolidated financial statements

and notes thereto are presented as a single reportable segment.

Historical Timeline

Fiscal Year	Filed
2025	Mar 2, 2026	Showing above
2024	Feb 27, 2025

2015	Mar 10, 2016

About Segments Disclosures

Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.

Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.

GERON CORP Segments Disclosure

Historical Timeline

About Segments Disclosures

Other Available Disclosures